Shopping Cart
- Remove All
- Your shopping cart is currently empty
TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | In Stock | |
50 mg | Inquiry | In Stock |
Description | TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia. |
Targets&IC50 | FGFR4:4045 nM, FGFR3:11 nM, FGFR2:157 nM, FGFR1:278 nM |
Alias | TYRA-300-B01, TYRA300 |
Molecular Weight | 559.47 |
Formula | C25H24Cl2N6O3S |
Cas No. | 2800223-30-5 |
Smiles | S(C)(=O)(=O)N1CC2(CN(C2)C3=CC=C(C=N3)C=4C=5C(NN4)=CC=C(O[C@H](C)C=6C(Cl)=CN=CC6Cl)C5)C1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (142.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.